Sanofi (SNY) announced that results from the PERSEUS phase 3 study showed that tolebrutinib did not meet its primary endpoint in delaying time to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback